Generic Name and Formulations:
Gadofosveset trisodium 244mg/mL (0.25mmol/mL); soln for IV inj.
Lantheus Medical Imaging
Indications for ABLAVAR:
For use as a contrast agent in magnetic resonance angiography (MRA) to evaluate aortoiliac occlusive disease (AIOD) in adults with known or suspected peripheral vascular disease.
Give as IV bolus inj over 30 seconds followed by 25–30mL normal saline flush. 0.12mL/kg (0.03mmol/kg). See full labeling for imaging guidelines.
<18yrs: not established.
Chronic, severe kidney disease (GFR<30mL/min/1.73m2), acute kidney injury: increased risk of nephrogenic systemic fibrosis; avoid unless necessary, allow sufficient period of time for elimination prior to re-administration. Screen for acute kidney injury and other conditions that reduce renal function (eg, >60yrs, hypertension, diabetes). Anaphylactoid reaction possible (may be fatal); discontinue immediately if occurs; have emergency resuscitative equipment available. History of drug reactions, asthma, allergy or other hypersensitivity disorders. Risk of QTc prolongation; consider obtaining baseline ECG to assess risk, consider follow up ECG and risk reduction measures until contrast agent eliminated. Pregnancy (Cat.C). Nursing mothers.
Gadolinium-based contrast agent.
Caution with concomitant drugs that bind to albumin.
Pruritus, headache, nausea, vasodilation, paresthesia, inj site bruising, dysgeusia, burning sensation, venipuncture site bruise, hypertension, dizziness, feeling cold; hypersensitivity reactions.
Single-use vials (10mL, 15mL)—10
Clinical Pain Advisor Articles
- Two Screening Tools May Accurately Predict Transition From Acute to Chronic Low Back Pain
- Predicting the Magnitude of Placebo Analgesia in Chronic Pain
- Operant Learning May Provide More Benefits Than Energy Conservation in Fibromyalgia
- Methamphetamine Use on the Rise in Patients With Opioid Use Disorder
- Tools to Address the Opioid Crisis
- The Unintended Consequences of the CDC Opioid Guideline According to Pain Management Specialists
- Initial Consultation for Neck Pain May Reduce Opioid Consumption, Healthcare Utilization
- FDA-Approved Test Provides Pharmacogenetic Reports Directly to Consumers
- Set of Interventions May Effectively Reduce Opioid Overprescribing
- Cannabinoid-Associated Analgesia May Be Mediated Through Modulation of Affective Processes
- Nonsinogenic Headache vs Chronic Rhinosinusitis Differential Diagnosis Based on SNOT-22 Patterns
- Patterns of Non-Medical Prescription Opioid Use in Adolescents
- Factors Promoting Participation in Self-Management Training Program for Chronic Pain
- Gendered Perceptions of Socially Acceptable Pain Relief Strategies
- Majority of Internists Still Have Financial Ties to Industry